ImmuCell Past Earnings Performance
Past criteria checks 0/6
ImmuCell's earnings have been declining at an average annual rate of -28.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 8.4% per year.
Key information
-28.4%
Earnings growth rate
-20.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 8.4% |
| Return on equity | -23.1% |
| Net Margin | -33.1% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ImmuCell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 17 | -6 | 5 | 4 |
| 30 Sep 23 | 16 | -6 | 6 | 4 |
| 30 Jun 23 | 16 | -6 | 5 | 5 |
| 31 Mar 23 | 16 | -5 | 5 | 5 |
| 31 Dec 22 | 19 | -2 | 5 | 4 |
| 30 Sep 22 | 20 | -1 | 5 | 5 |
| 30 Jun 22 | 20 | 0 | 5 | 4 |
| 31 Mar 22 | 21 | 1 | 5 | 4 |
| 31 Dec 21 | 19 | 0 | 4 | 4 |
| 30 Sep 21 | 18 | 0 | 4 | 4 |
| 30 Jun 21 | 16 | 0 | 4 | 4 |
| 31 Mar 21 | 15 | -1 | 4 | 4 |
| 31 Dec 20 | 15 | -1 | 4 | 4 |
| 30 Sep 20 | 15 | -2 | 4 | 4 |
| 30 Jun 20 | 14 | -2 | 4 | 4 |
| 31 Mar 20 | 14 | -2 | 4 | 4 |
| 31 Dec 19 | 14 | -1 | 4 | 4 |
| 30 Sep 19 | 13 | -2 | 4 | 4 |
| 30 Jun 19 | 12 | -2 | 4 | 4 |
| 31 Mar 19 | 13 | -2 | 4 | 4 |
| 31 Dec 18 | 11 | -2 | 4 | 4 |
| 30 Sep 18 | 11 | -1 | 4 | 3 |
| 30 Jun 18 | 11 | -2 | 4 | 3 |
| 31 Mar 18 | 10 | -1 | 3 | 2 |
| 31 Dec 17 | 10 | 0 | 3 | 2 |
| 30 Sep 17 | 10 | 0 | 3 | 2 |
| 30 Jun 17 | 9 | 0 | 3 | 1 |
| 31 Mar 17 | 10 | 1 | 3 | 1 |
| 31 Dec 16 | 10 | 1 | 3 | 1 |
| 30 Sep 16 | 10 | 1 | 3 | 1 |
| 30 Jun 16 | 11 | 1 | 3 | 1 |
| 31 Mar 16 | 10 | 1 | 3 | 1 |
| 31 Dec 15 | 10 | 1 | 3 | 1 |
| 30 Sep 15 | 10 | 1 | 3 | 1 |
| 30 Jun 15 | 9 | 1 | 3 | 1 |
| 31 Mar 15 | 9 | 0 | 3 | 2 |
| 31 Dec 14 | 8 | 0 | 2 | 2 |
| 30 Sep 14 | 7 | 0 | 2 | 2 |
| 30 Jun 14 | 6 | 0 | 2 | 2 |
| 31 Mar 14 | 6 | 0 | 2 | 1 |
| 31 Dec 13 | 6 | 0 | 2 | 1 |
| 30 Sep 13 | 6 | 0 | 2 | 1 |
| 30 Jun 13 | 6 | 0 | 2 | 1 |
Quality Earnings: IUL is currently unprofitable.
Growing Profit Margin: IUL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IUL is unprofitable, and losses have increased over the past 5 years at a rate of 28.4% per year.
Accelerating Growth: Unable to compare IUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IUL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: IUL has a negative Return on Equity (-23.1%), as it is currently unprofitable.